Prague Med. Rep. 2021, 122, 45-51

https://doi.org/10.14712/23362936.2021.6

Obstructive Jaundice Secondary to Pancreatic Head Metastasis of Malignant Amelanotic Melanoma as the First Clinical Manifestation

Jan Zeman1, Lucie Olivová2, Jan Hrudka3, Jan Hajer4, Ivan Rychlík1

1Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
2Department of Dermatology, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
3Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
4Department of Gastroenterology, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic

Received June 25, 2020
Accepted January 28, 2021

References

1. Capizzi, P. J., Donohue, J. H. (1994) Metastatic melanoma of the gastrointestinal tract: a review of the literature. Compr. Ther. 20, 20–23.
2. Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., Dummer, R., Sosman, J. A., Flaherty, K. T., Chang, I., Coleman, S., Caro, I., Hauschild, A., McArthur, G. A. (2017) Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study. Ann. Oncol. 28, 2581–2587. <https://doi.org/10.1093/annonc/mdx339>
3. Colovic, R. B., Grubor, N. M., Jovanovic, M. D., Micev, M. T., Colovic, N. R. (2007) Metastatic melanoma to the common bile duct causing obstructive jaundice: a case report. World J. Gastroenterol. 13, 813–815. <https://doi.org/10.3748/wjg.v13.i5.813>
4. Fidler, I. J. (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res. 50, 6130–6138.
5. Gualandri, L., Betti, R., Crosti, C. (2009) Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay. J. Eur. Acad. Dermatol. Venereol. 23, 283–287. <https://doi.org/10.1111/j.1468-3083.2008.03041.x>
6. Hauschild, A., Grob, J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H. Jr., Kaempgen, E., Martín-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A., Swann, S., Haney, P., Mirakhur, B., Guckert, M. E., Goodman, V., Chapman, P. B. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358–365. <https://doi.org/10.1016/S0140-6736(12)60868-X>
7. Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., Cruz-Merino, L., Dutriaux, C., Garbe, C., Sovak, M. A., Chang, I., Choong, N., Hack, S. P., McArthur, G. A., Ribas, A. (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867–1876. <https://doi.org/10.1056/NEJMoa1408868>
8. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., Ferrucci, P. F., Hill, A., Wagstaff, J., Carlino, M. S., Haanen, J. B., Maio, M., Marquez-Rodas, I., McArthur, G. A., Ascierto, P. A., Long, G. V., Callahan, M. K., Postow, M. A., Grossmann, K., Sznol, M., Dreno, B., Bastholt, L., Yang, A., Rollin, L. M., Horak, C., Hodi, F. S., Wolchok, J. D. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34. <https://doi.org/10.1056/NEJMoa1504030>
9. Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Kovalenko, N., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., DeMarini, D. J., Irani, J. G., Swann, S., Legos, J. J., Jin, F., Mookerjee, B., Flaherty, K. (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444–451. <https://doi.org/10.1016/S0140-6736(15)60898-4>
10. Marks, J. A., Rao, A. S., Loren, D., Witkiewitz, A., Mastrangelo, M. J., Berger, A. C. (2010) Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the ampulla of Vater. JOP 11, 173–175.
11. Meyers, M. O., Frey, D. J., Levine, E. A. (1998) Pancreaticoduodenectomy for melanoma metastatic to the duodenum: a case report and review of the literature. Am. Surg. 64, 1174–1176.
12. Parquier, J. N., Peetrons, P., Liénard, D., Maisonnier, H., Jeanmart, L. (1991) Jaundice secondary to a metastasis of a malignant melanoma at the level of the common bile duct. J. Belge Radiol. 74, 201–204.
13. Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hauschild, A., Lorigan, P., Wolter, P., Long, G. V., Flaherty, K., Nathan, P., Ribas, A., Martin, A., Sun, P., Crist, W., Legos, J., Rubin, S. D., Little, S. M., Schadendorf, D. (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30–39. <https://doi.org/10.1056/NEJMoa1412690>
14. Sans, M., Llach, J., Bordas, J. M., Andreu, V., Campo, A., Castells, A., Mondelo, E., Terés, J., Rodés, J. (1996) Metastatic malignant melanoma of the papilla of Vater: An unusual case of obstructive cholestasis treated with biliary prostheses. Endoscopy 28, 791–792. <https://doi.org/10.1055/s-2007-1005618>
15. Sullivan, R. J., Hamid, O., Gonzalez, R., Infante, J. R., Patel, M. R., Hodi, F. S., Lewis, K. D., Tawbi, H. A., Hernandez, G., Wongchenko, M. J., Chang, Y., Roberts, L., Ballinger, M., Yan, Y., Cha, E., Hwu, P. (2019) Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929–935. <https://doi.org/10.1038/s41591-019-0474-7>
16. Swaika, A., Crozier, J. A., Joseph, W. R. (2014) Vemurafenib: An evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des. Devel. Ther. 8, 775–787.
17. Thompson, J. F., Mathur, M. N., Coates, A. S. (1993) Common bile duct obstruction due to intraluminal metastatic melanoma. Aust. N. Z. J. Surg. 63, 502–504. <https://doi.org/10.1111/j.1445-2197.1993.tb00438.x>
18. Umemura, M., Chida, T., Matsunaga, E., Ito, J., Ohta, K., Shimoyama, S., Yamazaki, S., Kawata, K., Ono, T., Kobayashi, Y. (2018) A case of obstructive pancreatitis induced by extramedullary pancreatic metastasis in a patient with immunoglobulin D multiple myeloma. Nihon Shokakibyo Gakkai Zasshi 115, 914–922.
19. Van Bokhoven, M. M., Aarntzen, E. H., Tan, A. C. (2006) Metastatic melanoma of the common bile duct and ampulla of Vater. Gastrointest. Endosc. 63, 873–874. <https://doi.org/10.1016/j.gie.2005.12.023>
20. Wee, E., Wolfe, R., Mclean, C., Kelly, J. W., Pan, Y. (2018) Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival. J. Am. Acad. Dermatol. 79, 645–651. <https://doi.org/10.1016/j.jaad.2018.04.045>
21. Zheng, S., Zhou, D., Chen, Y., Jiang, R., Wang, Y., Zhang, Y., Xue, H., Wang, H., Mou, D., Zeng, W. (2017) Pancreatic T/histiocyte-rich large B-cell lymphoma: A case report and review of literature. World J. Gastroenterol. 23, 4467–4472. <https://doi.org/10.3748/wjg.v23.i24.4467>
front cover

ISSN 1214-6994 (Print) ISSN 2336-2936 (Online)

Archive